Kiran Bhavaraju-Sanka, MD, and Beth Stein, MD, focus on the best and most effective methods of engaging patients who have ...

Telitacicept met primary and all secondary endpoints, demonstrating clinically meaningful improvements in disease activity versus placebo~71.8% ...

The acquisition of the well-funded startup is the fourth this year involving companies with technologies that can genetically modify immune cells inside the body.

Regeneron's revenue in the second quarter increased by 4% year over year to $3.68 billion. That's not phenomenal top-line growth, but it's pretty strong considering Eylea's challenges. Furthermore, ...

DexCom › One way to earn above-average market returns -- which isn't always easy -- is to invest in companies that have lagged the market but are likely to recover over the long run. As the basic ...

The ClearBridge Value Equity Strategy underperformed its Russell 1000 Value Index during the third quarter. Read more here.

With no weight-loss drug and a focus on cancer, the FTSE 100 giant needs to perfectly manage its patent cliff-edge ...

Myasthenia gravis is a rare disease where the immune system attacks the communication between nerves and muscles, causing weakness. It often affects the muscles used for eye movement, facial ...

Generalized myasthenia gravis (gMG) affects most patients through a handful of well-characterized neuromuscular junction autoantibodies, but a wide range of differences among patients affect the ...

"Myasthenia Gravis Market"Myasthenia Gravis companies such as Horizon Therapeutics, Amgen, Janssen Research & Development, LLC, Hoffmann-La Roche, Immunovant Sciences GmbH, Alexion, AstraZeneca Rare ...

It's important to enhance MG treatment outcomes with strong provider-patient relationships and ongoing monitoring, explain Ratna Kiran Bhavaraju-Sanka, MD, and Beth Stein, MD. There is a critical need ...

Clinicians in Europe may soon gain access to a first-in-class neonatal Fc receptor (FcRn) inhibitor for generalized myasthenia gravis (gMG). Imaavy (nipocalimab; Janssen-Cilag International) received ...